Dr. Jun Liao
CEO

Dr.Jun Liao worked as a PI at ShanghaiTech University, where he led several national projects aiming at high-impact technological innovations in membrane protein structural biology - One national key project of “Protein Machinery and Life Process Regulation” - Two national major projects of the 13th Five-Year Drug Initiative of China - One national general project founded by the National Natural Science Foundation - One Shanghai Plateau Project, which aims at promoting world-leading technological innovations

Dr. Minghui Li
CTO

Dr. Minghui Li obtained his Ph.D. from the Chinese Academy of Sciences in Dr. Dongcai Liang’s lab and did the postdoctoral research at Columbia University with Dr. Jian Yang. Minghui developed MegaR & MegAb platform technology, which is especially powerful in : - production of difficult-to-express GPCRs - cryo-EM structure determination of small-size GPCRs in complexes with antagonists - GPCR antibody drug discovery Minghui has solved cryo-EM structures of: - first eukaryotic cyclic nucleotide-gated channel - human TRPML3 channel in three distinct states - Plasmodium falciparum multi-drug resistant (MDR) 1 transporter in different conformations